KMT2A and acute myeloid leukemia: It has been demonstrated that other HDAC inhibitors, such as I3 [45] and I13 [46], are strong chromatin‐remodeling agents that can overcome the differentiation block in AML patients, including those with t(8; 21) translocation or KMT2A rearrangements.